Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a

Status Completed

Clinical Trial Summary

In this feasibility study the investigators intend to treat patients with high mutational uterine cancer with two cycles immune checkpoint inhibition before standard-of-care hysterectomy.

Clinical Trial Description

Objective: The investigators aim to establish proof-of-concept for use of immune checkpoint blockade (ICB) as novel neo-adjuvant therapy in (deficient mismatch repair) dMMR and (Polymerase ε mutation)POLE-EDM uterine cancer (UC). When ICB proves to be feasible as defined in the primary endpoint, a follow-up with a larger multicenter studies to determine clinical efficacy, such as postponing standard-of-care surgery or randomized studies to standard-of-care. Study design: The investigators planned a window-of-opportunity study of ICB in primary dMMR UC (n=10) and primary POLE-EDM UC (n=10) patients. ICB (pembrolizumab; anti-PD1) will be administered in two cycles of 3 weeks between diagnosis and standard-of-care hysterectomy. Tumor responses to pembrolizumab will be assessed 3 weeks after the second cycle of pembrolizumab by a pathologist (primary endpoint) and MRI (secondary endpoint).After treatment with immun checkpoint blockade a hysterectomy will take place (standard-of care). Peripheral blood and tumor samples will be used to evaluate immune responses. Study population: Primary dMMR/ POLE-EDM UC patients of any stage and/or grade who are intended to be treated with a hysterectomy recruited from the North-Netherlands oncological region. Intervention: Pembrolizumab, 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care. Main study endpoints: The primary endpoint is the response rate of the tumor assessed by pathology in uterine cancer patients treated with neo-adjuvant pembrolizumab. The secondary endpoint is the objective response rate of the tumor by MRI using RECIST. Exploratory objectives are immunogenicity, safety and the value of a pipelle biopsy as a predictor for response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04262089
Study type	Interventional
Source	University Medical Center Groningen
Contact
Status	Completed
Phase	Phase 1
Start date	November 1, 2020
Completion date	November 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03285802` - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Phase 2/Phase 3
Completed	`NCT01870947` - Assisted Exercise in Obese Endometrial Cancer Patients	N/A
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Not yet recruiting	`NCT05998811` - Insights Into Participating in Studies for Uterine Cancer
Not yet recruiting	`NCT06369155` - Azenosertib in Uterine Serous Carcinoma: Biomarker Study	Phase 2
Completed	`NCT01399658` - Image-Guided Gynecologic Brachytherapy	Phase 2
Completed	`NCT01432015` - Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting	Phase 4
Recruiting	`NCT02349958` - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy	Phase 2
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A
Completed	`NCT00284427` - Safety of Antioxidants During GYN Cancer Care	Phase 2
Completed	`NCT00147680` - Uterine Papillary Serous Cancer (UPSC) Trial	Phase 2
Recruiting	`NCT05743517` - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)	N/A
Recruiting	`NCT05916196` - [18F]FES PET/.CT in Uterine Cancer	Phase 2
Withdrawn	`NCT04368130` - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care	N/A
Active, not recruiting	`NCT03668340` - AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Phase 2
Completed	`NCT00588640` - Study of D-Methadone in Patients With Chronic Pain	Phase 1/Phase 2
Recruiting	`NCT05990426` - Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	N/A
Completed	`NCT03701529` - Effect of Anesthetic Agents on Optic Nerve Sheath Diameter	N/A
Recruiting	`NCT05758688` - Whole Pelvis Proton Radiation for Gynecologic Cancer	N/A
Completed	`NCT01953107` - Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study — PAM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms